Evidence map›Paper›PMID 25558350›Full record

ArticleJournal of clinical bioinformatics2014

Copy number variation analysis based on AluScan sequences.

Jian-Feng Yang, Xiao-Fan Ding, Lei Chen, Wai-Kin Mat, Michelle Zhi Xu, Jin-Fei Chen, Jian-Min Wang, Lin Xu, Wai-Sang Poon, Ava Kwong and 15 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical bioinformatics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 2 countries.

Jian-Feng Yang *Division of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Xiao-Fan Ding *Division of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Lei ChenNational Center for Liver Cancer Research and Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai, 200438 China.
Wai-Kin MatDivision of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Michelle Zhi XuDepartment of Oncology, Nanjing First Hospital, No. 68 Changle Road, Nanjing, 210006 China.
Jin-Fei ChenDepartment of Oncology, Nanjing First Hospital, No. 68 Changle Road, Nanjing, 210006 China.
Jian-Min WangDepartment of Hematology, Changhai Hospital, Second Military Medical University, 174 Changhai Road, Shanghai, 200433 China.
Lin XuDepartment of Thoracic Surgery, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Baiziting 42, Nanjing, 210009 China.
Wai-Sang PoonDivision of Neurosurgery, Department of Surgery, Prince of Wales Hospital, Chinese University of Hong Kong, 30-32 Ngan Shing Street, Sha Tin, Hong Kong, China.
Ava KwongDivision of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
Gilberto Ka-Kit LeungDivision of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
Tze-Ching TanDepartment of Neurosurgery, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, China.
Chi-Hung YuDepartment of Neurosurgery, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong, China.
Yue-Bin KeShenzhen Center for Disease Control and Prevention, No 8 Longyuan Road, Nanshan district, Shenzhen City, 518055 China.
Xin-Yun XuShenzhen Center for Disease Control and Prevention, No 8 Longyuan Road, Nanshan district, Shenzhen City, 518055 China.
Xiao-Yan KeNanjing Brain Hospital and Nanjing Institute of Neuropsychiatry, Nanjing Medical University, Nanjing, 210029 China.
Ronald Cw MaDepartment of Medicine and Therapeutics, 9th floor, Clinical Sciences Building, The Prince of Wales Hospital, Shatin, Hong Kong.
Juliana Cn ChanDepartment of Medicine and Therapeutics, 9th floor, Clinical Sciences Building, The Prince of Wales Hospital, Shatin, Hong Kong.
Wei-Qing WanDepartment of Neurosurgery, Beijing Tiantan Hospital, 6 Tiantan Xili, Dongcheng District, Capital Medical University, Beijing, 100050 China.
Li-Wei ZhangDepartment of Neurosurgery, Beijing Tiantan Hospital, 6 Tiantan Xili, Dongcheng District, Capital Medical University, Beijing, 100050 China.
Yogesh KumarDivision of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Shui-Ying TsangDivision of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Shao LiMOE Key Laboratory of Bioinformatics and Bioinformatics Division, TNLIST, Department of Automation, Tsinghua University, Beijing, 100084 China.
Hong-Yang WangNational Center for Liver Cancer Research and Eastern Hepatobiliary Surgery Hospital, 225 Changhai Road, Shanghai, 200438 China.
Hong XueDivision of Life Science and Applied Genomics Centre, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Hong Kong University of Science and Technology · HKSecond Military Medical University · CN81th Hospital of PLA · CNCapital Medical University · CNPrince of Wales Hospital · CNQueen Elizabeth Hospital · CNQueen Mary Hospital · CNShenzhen Center for Disease Control and Prevention · CNChinese University of Hong Kong · HKJiangsu Cancer Hospital · CNNanjing Brain Hospital · CNTsinghua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAluScan combines inter-Alu PCR using multiple Alu-based primers with opposite orientations and next-generation sequencing to capture a huge number of Alu-proximal genomic sequences for investigation. Its requirement of only sub-microgram quantities of DNA facilitates the examination of large numbers of samples. However, the special features of AluScan data rendered difficult the calling of copy number variation (CNV) directly using the calling algorithms designed for whole genome sequencing (WGS) or exome sequencing.

resultsIn this study, an AluScanCNV package has been assembled for efficient CNV calling from AluScan sequencing data employing a Geary-Hinkley transformation (GHT) of read-depth ratios between either paired test-control samples, or between test samples and a reference template constructed from reference samples, to call the localized CNVs, followed by use of a GISTIC-like algorithm to identify recurrent CNVs and circular binary segmentation (CBS) to reveal large extended CNVs. To evaluate the utility of CNVs called from AluScan data, the AluScans from 23 non-cancer and 38 cancer genomes were analyzed in this study. The glioma samples analyzed yielded the familiar extended copy-number losses on chromosomes 1p and 9. Also, the recurrent somatic CNVs identified from liver cancer samples were similar to those reported for liver cancer WGS with respect to a striking enrichment of copy-number gains in chromosomes 1q and 8q. When localized or recurrent CNV-features capable of distinguishing between liver and non-liver cancer samples were selected by correlation-based machine learning, a highly accurate separation of the liver and non-liver cancer classes was attained.

conclusionsThe results obtained from non-cancer and cancerous tissues indicated that the AluScanCNV package can be employed to call localized, recurrent and extended CNVs from AluScan sequences. Moreover, both the localized and recurrent CNVs identified by this method could be subjected to machine-learning selection to yield distinguishing CNV-features that were capable of separating between liver cancers and other types of cancers. Since the method is applicable to any human DNA sample with or without the availability of a paired control, it can also be employed to analyze the constitutional CNVs of individuals.

Indexed as

AluScan sequencingCancer classificationCNV callingMachine learning

Identifiers

PMID25558350
PMCPMC4273479
OpenAlexW2108910098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.